Non-Invasive Plasma Treatment Shows Promise for Cervical Precancer

Persistent infection with high-risk strains of human papillomavirus (HPV) frequently leads to precancerous changes in the cervix, known as cervical intraepithelial neoplasia (CIN). A new, non-invasive treatment option, non-invasive physical plasma treatment (NIPP), is emerging as a potential alternative to traditional surgical procedures.

The Challenges of Current Treatment Approaches

CIN is graded from 1 to 3, with higher grades indicating more significant abnormalities. Whereas often resolving on their own, CIN 2 lesions, in particular, carry a significantly increased risk of developing into cervical cancer over two decades if left untreated [1]. Currently, loop electrosurgical excision procedure (LLETZ) is a common treatment, but it’s invasive and can lead to tissue loss, potentially impacting fertility and increasing the risk of complications in future pregnancies.

This creates a clinical dilemma: overtreating with invasive procedures versus undertreating and risking cancer progression.

Introducing Non-Invasive Physical Plasma Treatment (NIPP)

NIPP offers a novel approach by utilizing gentle, topical plasma energy to treat CIN without removing cervical tissue. The procedure is performed in an outpatient setting and does not require anesthesia. Early studies suggest NIPP effectively addresses the gap between the risks of undertreatment and the drawbacks of invasive surgery.

Clinical Trial Demonstrates Potential Superiority

A recent multicenter, prospective, controlled, randomized and single-blind clinical study is underway to demonstrate the superiority of NIPP over active surveillance – a “watch and wait” approach – for CIN 2. The study focuses on evaluating CIN 2 remission rates through histopathological analysis [2]. Researchers are also assessing the impact of NIPP on patients’ quality of life by providing a non-invasive treatment alternative.

Impact of HPV Vaccination on CIN Rates

The introduction of HPV vaccination has significantly reduced infections with vaccine-type HPV, reshaping cervical cancer prevention. Studies demonstrate a greater than 50% reduction in the risk of CIN2+ in vaccinated women, with a 95% reduction in CIN2+ related to HPV types 16 and 18 [2]. However, CIN2+ can still occur due to non-vaccine high-risk HPV types, even after vaccination, highlighting the continued necessitate for effective treatment options.

Future Outlook

If the ongoing clinical trials confirm its effectiveness, NIPP has the potential to grow a standard treatment for CIN 2 worldwide, offering women a less invasive and potentially more fertility-sparing option. Further research will be crucial to determine the long-term efficacy and safety of NIPP, as well as its role in managing CIN in vaccinated populations.

Disclaimer: This article provides general information and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.